Of these patients, one was an 82-year-old female treated with relapse/refractory multiple myeloma that had been treated over 3 years (last line therapy included anti-B-cell maturation antigen bispecific antibody), with a medical history of colorectal carcinoma post-hemicolectomy and adjuvant chemotherapy, and, moreover, with a history of arterial hypertension and chronic kidney disease. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.